新开源8月26日披露的半年报显示，公司上半年实现营业收入6.44亿元，同比下降12.36%；归属于上市 公司股东的净利润1.39亿元，同比下降34.74%；基本每股收益0.29元。 ...

博爱新开源医疗科技集团股份有限公司 2025 年半年度报告全文 博爱新开源医疗科技集团股份有限公司 2025 年半年度报告 2025 年 8 月 博爱新开源医疗科技集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人张军政、主管会计工作负责人刘爱民及会计机构负责人(会计 主管人员)李春平声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 请投资者注意阅读本报告"第三节 管理层讨论与分析"之"第十条、公 司面临的风险和应对措施"对公司风险提示的相关内容，敬请广大投资者注 意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 8 | | | 第三节 | 管理层讨论与分析 11 | | | 第四节 | 公司治理、环境和社会 58 | ...

金融界消息 截至2025年8月25日收盘，新开源（300109）报收于18.45元，上涨0.16%，换手率4.35%， 成交量19.56万手，成交金额3.61亿元。 资金流向方面，今日主力资金净流出1351.15万元，占比成交额3.74%。其中，超大单净流出160.84万 元、占成交额0.45%，大单净流出1190.31万元、占成交额3.29%，中单净流出流入340.53万元、占成交 额0.94%，小单净流入1010.61万元、占成交额2.8%。 新开源最新一期业绩显示，截至2025一季报，公司营业总收入3.25亿元、同比减少17.69%，归属净利润 8042.03万元，同比减少33.75%，扣非净利润6941.62万元，同比减少44.85%，流动比率2.565、速动比率 2.016、资产负债率18.03%。 通过天眼查大数据分析，博爱新开源医疗科技集团股份有限公司共对外投资了19家企业，参与招投标项 目34次，知识产权方面有商标信息56条，专利信息56条，此外企业还拥有行政许可95个。 来源：金融界 天眼查商业履历信息显示，博爱新开源医疗科技集团股份有限公司，成立于2003年，位于焦作市，是一 家以从事医药 ...

Group 1 - The company has not yet supplied its PVP products directly to relevant robotics companies as of August 22 [1] - The company will continue to explore potential downstream demand for PVP in electronic skin applications by leveraging its performance advantages [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xin Kai Yuan, which closed at 18.42 yuan with a PE ratio of 29.00, marking a new low in 297 days, and a total market capitalization of 8.953 billion yuan [1] - The chemical products industry has an average PE ratio of 50.34, with a median of 43.76, positioning Xin Kai Yuan at the 73rd rank within the industry [1] - The company experienced a net inflow of 43.83 million yuan in principal funds on August 22, with a total inflow of 4.0141 million yuan over the past five days [1] Group 2 - Xin Kai Yuan's main business focuses on fine chemicals and precision medicine, with key products including PVPK30, PVP-I, and various diagnostic services [1] - The latest financial results for Q1 2025 show a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75%, with a gross margin of 44.07% [1] - The PE ratios for Xin Kai Yuan are 29.00 (TTM) and 25.60 (static), with a price-to-book ratio of 2.41 [2]

天眼查商业履历信息显示，博爱新开源医疗科技集团股份有限公司，成立于2003年，位于焦作市，是一 家以从事医药制造业为主的企业。企业注册资本48605.0005万人民币，实缴资本48470.0005万人民币。 公司法定代表人为张军政。 通过天眼查大数据分析，博爱新开源医疗科技集团股份有限公司共对外投资了19家企业，参与招投标项 目34次，知识产权方面有商标信息56条，专利信息56条，此外企业还拥有行政许可95个。 来源：金融界 金融界消息 截至2025年8月22日收盘，新开源（300109）报收于18.42元，上涨1.49%，换手率4.69%， 成交量21.09万手，成交金额3.87亿元。 资金流向方面，今日主力资金净流入4383.46万元，占比成交额11.34%。其中，超大单净流入81.70万 元、占成交额0.21%，大单净流入4301.76万元、占成交额11.13%，中单净流出流出658.21万元、占成交 额1.7%，小单净流出3725.25万元、占成交额9.64%。 新开源最新一期业绩显示，截至2025一季报，公司营业总收入3.25亿元、同比减少17.69%，归属净利润 8042.03万元，同比减少33. ...

Core Viewpoint - The company has not yet supplied its PVP products directly to relevant robotics companies, but it aims to actively explore downstream potential demand through the performance advantages of PVP in applications such as electronic skin [1] Group 1 - The company is currently focused on expanding the application of its PVP products in the electronic skin sector [1] - There is an emphasis on leveraging the performance advantages of PVP to tap into potential market needs [1]

Core Viewpoint - The company, New Open Source (300109), has not yet supplied its PVP products directly to relevant robotics companies, indicating a current lack of market penetration in this sector [1] Group 1: Company Developments - As of now, the company's PVP products have not been supplied to related robotics enterprises [1] - The company plans to leverage the performance advantages of its PVP products to actively explore potential downstream demand in the application of electronic skin [1]

Financial Performance - As of the closing on August 19, 2025, the company's stock price was 18.08 yuan, down 0.82% with a turnover rate of 3.76% and a trading volume of 169,100 hands, amounting to 305 million yuan in transaction value [1] - The latest quarterly report shows total revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit attributable to shareholders of 80.42 million yuan, down 33.75% year-on-year [1] - The company's non-recurring net profit was 69.42 million yuan, reflecting a year-on-year decrease of 44.85% [1] - The liquidity ratios are as follows: current ratio at 2.565, quick ratio at 2.016, and debt-to-asset ratio at 18.03% [1] Investment and Business Activities - The company has made investments in 19 enterprises and participated in 34 bidding projects [2] - It holds 56 trademark registrations and 56 patent registrations, along with 95 administrative licenses [2] Company Background - Founded in 2003, the company is based in Jiaozuo City and primarily engages in the pharmaceutical manufacturing industry [1] - The registered capital is approximately 4.86 billion yuan, with paid-in capital of about 4.85 billion yuan [1]

Group 1 - The core transaction involved 550,000 shares of Xin Kai Yuan, with a total transaction value of 7.7825 million yuan, accounting for 4.18% of the total transaction volume on that day [1][2] - The transaction price was 14.15 yuan per share, which represents an 18.72% discount compared to the market closing price of 17.41 yuan [1][2] Group 2 - The buyer was China International Capital Corporation Wealth Securities, while the seller was China Galaxy Securities Co., Ltd. [2] - The transaction occurred on August 12, 2025, under the stock code 300109 for Xin Kai Yuan [2]